We have investigated the possible relation between serum levels of CA 15.3 and disease status in 110 patients after radical mastectomy for breast cancer, with metastatic diffusion. Its persistant elevation was usually related to a very poor prognosis.
In patients who died within 18 months the marker was always elevated. In case of progression of the disease, the marker level appeared to be consistently correlated with the general clinical condition. In healthy patients with stable disease the marker remained near the normal range.
WangD.Y., BulbrookR.D., HaywardJ.L., HendrickJ.C., FranchimontP.Relationship between plasma CEA and prognosis in women with breast cancer. Eur J Cancer1975; 11: 615–9.
2.
HayesD.F., ZurawskiV.R., KufeD.W.Comparison of circulating CA 15.3 and CEA levels in patients with breast cancer. J Clin Oncol1986; 4: 1542–50.
3.
BeardD.B., HeskellC.CEA in breast cancer. Am J Med1986; 80: 241–5.
4.
TormeyD., WaalkesT.Clinical correlation between CEA and breast cancer. Cancer1978; 42: 1507–11.
5.
GangY., AdachiI., OhkuraH.CA 15.3 is present as a novel marker in the sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho1985; 12: 2379–81.
6.
NamerM., KrebsB.P., RameauP.Le marqueurs tumoraux dans le cancer du sein: comment le utiliser en 1985? In: Demaille, ed. Le maladies du sein en 1985: formation médicale continue en sénologie. 7 èrne journée de la Société Francaise de Sénologie et Pathologie Mammaire, 1985; 20.
7.
BallestaA.M., MolinaR., MarinJ.L.A new tumor marker CA 15.3 defined by monoclonal antibodies. Initial clinical evaluation in patients with breast cancer. Proc. XIII Annual Meeting ISOBM; Paris, 1985.
8.
FujinoN., HagaY., SakamotoK.Clinical evaluation of an immunoradiometric assay for CA 15.3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Jap J Clin Oncol1986; 16: 335–46.
9.
OgawaT., IzuoM., MoritaH.Evaluation of a tumor associated antigen CA 15.3 in the sera of patients with breast cancer. Gan To Rinsho1986; 32: 27–31.
10.
Pons-AnicetD.M.F., KrebsB.P., MiraR., NamerM.Value of CA 13.5 in the follow-up of breast cancer patients. Br J Cancer1987; 55: 567–9.
11.
KerinM.J., McAnenaO.J.CA 15.3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg1989; 76: 838–9.
12.
KobayashiS., IwaseH.The clinical value of serum CA 13.5 assay postoperatively in breast cancer patients. Jap J Surg1989; 3: 278–82.
13.
MughalA.W., HortobagyiG.N., FritscheH.A.Serial plasma CEA measurements during treatment of metastatic breast cancer. JAMA1983; 249: 14, 1881–6.
14.
MaigreM., FumeleauP., RicolleauG., GuillardY., CussacA., VignoudJ., AhkongV.Le CA 13.5 dans le cancer du sein. Comparaison avec l'ACE. Sem Hop Paris1988; 64, 1: 9–13.
15.
ThirionB., BarretB.Results of a multicentric study with CA 15.3 new tumor marker for breast cancer (poster). Symposium CIS. Paris, janvier 1987.
